Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab
Clinical trial NCT03553823 · COMPLETED
Trial details
- NCT number
- NCT03553823
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-01-14
- Primary completion
- 2020-01-28
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.